SLC13A5 and Other metabolic disease: While there are no genetic association studies linking SLC13A5 variants to human metabolic diseases [61], data from cell-based, mouse, and human studies indicate that inhibition of mINDY comprises an interesting and promising strategy to target metabolic and cardiovascular traits within the cardiometabolic disease spectrum.